

Underwood Thomas
 Form 3
 October 02, 2009

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2005
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Underwood Thomas		(Month/Day/Year)	INVERNESS MEDICAL INNOVATIONS INC [IMA]	
(Last)	(First)	(Middle)	09/24/2009	
3200 WINDY HILL ROAD,Â SUITE B-100			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
ATLANTA,Â GAÂ 30339			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			Chief Information Officer	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	--	---	--

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of Shares			

(Instr. 5)

Employee Stock Option (Right to Buy)	Â (1)	08/31/2019	Common Stock	40,000	\$ 35.6	D	Â
Employee Stock Option (Right to Buy)	Â (2)	06/30/2019	Common Stock	12,000	\$ 35.58	D	Â
Employee Stock Option	Â (3)	12/13/2018	Common Stock	1,000	\$ 18.91	D	Â
Employee Stock Option (Right to Buy)	Â (4)	06/30/2018	Common Stock	25,000	\$ 33.17	D	Â
Series B Convertible Perpetual Preferred Stock	Â (5)	Â (6)	Common Stock	22,636 (7)	\$ 69.32 (5)	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Underwood Thomas 3200 WINDY HILL ROAD SUITE B-100 ATLANTA, GA 30339	Â	Â	Â Chief Information Officer	Â

Signatures

/s/ Jay McNamara, Attorney
in Fact

10/02/2009

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option becomes exercisable in four equal annual installments beginning August 31, 2010.
- (2) This option becomes exercisable in four equal annual installments beginning June 30, 2010.
- (3) This option becomes exercisable in four equal annual installments beginning December 31, 2009.
- (4) This option becomes exercisable in four equal annual installments beginning June 30, 2009.
- (5) Convertible at \$69.32, subject to customary antidilution adjustments, if during any calendar quarter the closing price of the common stock exceeds 130% of the Series B conversion price then in effect and in certain other circumstances.
- (6) The Series B preferred stock has no expiration date.
- (7) Each share of Series B preferred stock is convertible, based on a liquidation preference of \$400.00 per share into 5.7703 shares of common stock, plus cash in lieu of fractional shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.